(MEDP) Medpace Holdings - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58506Q1094
Stock: Clinical Trials, Drug Development, Medical Devices, Research Services
Total Rating 68
Risk 61
Buy Signal 0.11
| Risk 5d forecast | |
|---|---|
| Volatility | 44.7% |
| Relative Tail Risk | -16.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 17.86 |
| Character TTM | |
|---|---|
| Beta | 1.055 |
| Beta Downside | 0.815 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.38% |
| CAGR/Max DD | 0.95 |
EPS (Earnings per Share)
Revenue
Description: MEDP Medpace Holdings March 04, 2026
Medpace Holdings, Inc. (MEDP) is a contract research organization (CRO) providing drug and medical device development services globally. CROs support pharmaceutical, biotechnology, and medical device companies by outsourcing clinical trial activities.
The company offers a comprehensive range of services across all phases of clinical development (I-IV). This includes study design, central laboratory services, project management, regulatory affairs, clinical monitoring, data management, and pharmacovigilance. This full-service model is common in the CRO industry, allowing clients to streamline their research and development processes.
Additional services include bio-analytical laboratory testing, clinical human pharmacology, imaging services, and electrocardiography reading support. These specialized offerings enhance the companys capabilities in supporting complex clinical trials.
To gain further insights into MEDPs financial performance and market position, consider exploring its detailed financials on ValueRay.
Headlines to watch out for
- Biotechnology R&D spending directly impacts Medpace revenue
- Regulatory changes in drug approval processes create uncertainty
- Competition from other CROs pressures Medpace pricing
- Biotech funding environment influences new study initiations
- Labor costs for scientific personnel affect profitability
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 451.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.36 > 0.02 and ΔFCF/TA 8.63 > 1.0 |
| NWC/Revenue: -14.00% < 20% (prev -3.57%; Δ -10.42% < -1%) |
| CFO/TA 0.36 > 3% & CFO 713.2m > Net Income 451.1m |
| Net Debt (-246.6m) to EBITDA (551.9m): -0.45 < 3 |
| Current Ratio: 0.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.0m) vs 12m ago -9.53% < -2% |
| Gross Margin: 30.06% > 18% (prev 0.31%; Δ 2.97k% > 0.5%) |
| Asset Turnover: 124.1% > 50% (prev 100.4%; Δ 23.75% > 0%) |
| Interest Coverage Ratio: -115.7 > 6 (EBITDA TTM 551.9m / Interest Expense TTM -4.65m) |
Altman Z'' -0.48
| A: -0.18 (Total Current Assets 989.6m - Total Current Liabilities 1.34b) / Total Assets 1.98b |
| B: -0.23 (Retained Earnings -460.0m / Total Assets 1.98b) |
| C: 0.26 (EBIT TTM 537.7m / Avg Total Assets 2.04b) |
| D: -0.31 (Book Value of Equity -464.6m / Total Liabilities 1.52b) |
| Altman-Z'' Score: -0.48 = B |
Beneish M -2.91
| DSRI: 1.13 (Receivables 402.1m/296.4m, Revenue 2.53b/2.11b) |
| GMI: 1.04 (GM 30.06% / 31.12%) |
| AQI: 0.96 (AQ_t 0.37 / AQ_t-1 0.39) |
| SGI: 1.20 (Revenue 2.53b / 2.11b) |
| TATA: -0.13 (NI 451.1m - CFO 713.2m) / TA 1.98b) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of MEDP shares?
As of March 16, 2026, the stock is trading at USD 450.41 with a total of 327,672 shares traded.
Over the past week, the price has changed by -5.88%, over one month by +5.19%, over three months by -19.44% and over the past year by +38.02%.
Over the past week, the price has changed by -5.88%, over one month by +5.19%, over three months by -19.44% and over the past year by +38.02%.
Is MEDP a buy, sell or hold?
Medpace Holdings has received a consensus analysts rating of 3.33.
Therefor, it is recommend to hold MEDP.
- StrongBuy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MEDP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 489.7 | 8.7% |
| Analysts Target Price | 489.7 | 8.7% |
MEDP Fundamental Data Overview March 16, 2026
P/E Trailing = 29.4964
P/E Forward = 26.5957
P/S = 5.0522
P/B = 27.8483
P/EG = 2.2532
Revenue TTM = 2.53b USD
EBIT TTM = 537.7m USD
EBITDA TTM = 551.9m USD
Long Term Debt = 113.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 23.2m USD (from shortTermDebt, last quarter)
Debt = 250.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -246.6m USD (from netDebt column, last quarter)
Enterprise Value = 12.54b USD (12.78b + Debt 250.5m - CCE 497.0m)
Interest Coverage Ratio = -115.7 (Ebit TTM 537.7m / Interest Expense TTM -4.65m)
EV/FCF = 17.69x (Enterprise Value 12.54b / FCF TTM 708.7m)
FCF Yield = 5.65% (FCF TTM 708.7m / Enterprise Value 12.54b)
FCF Margin = 28.01% (FCF TTM 708.7m / Revenue TTM 2.53b)
Net Margin = 17.83% (Net Income TTM 451.1m / Revenue TTM 2.53b)
Gross Margin = 30.06% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.77b) / Revenue TTM)
Gross Margin QoQ = 28.98% (prev 29.84%)
Tobins Q-Ratio = 6.35 (Enterprise Value 12.54b / Total Assets 1.98b)
Interest Expense / Debt = 3.15% (Interest Expense 7.88m / Debt 250.5m)
Taxrate = 13.84% (21.7m / 156.8m)
NOPAT = 463.3m (EBIT 537.7m * (1 - 13.84%))
Current Ratio = 0.74 (Total Current Assets 989.6m / Total Current Liabilities 1.34b)
Debt / Equity = 0.55 (Debt 250.5m / totalStockholderEquity, last quarter 459.1m)
Debt / EBITDA = -0.45 (Net Debt -246.6m / EBITDA 551.9m)
Debt / FCF = -0.35 (Net Debt -246.6m / FCF TTM 708.7m)
Total Stockholder Equity = 379.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.13% (Net Income 451.1m / Total Assets 1.98b)
RoE = 118.8% (Net Income TTM 451.1m / Total Stockholder Equity 379.7m)
RoCE = 109.0% (EBIT 537.7m / Capital Employed (Equity 379.7m + L.T.Debt 113.6m))
RoIC = 122.0% (NOPAT 463.3m / Invested Capital 379.7m)
WACC = 9.66% (E(12.78b)/V(13.03b) * Re(9.80%) + D(250.5m)/V(13.03b) * Rd(3.15%) * (1-Tc(0.14)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.60%
[DCF] Terminal Value 76.05% ; FCFF base≈654.1m ; Y1≈806.9m ; Y5≈1.37b
[DCF] Fair Price = 619.4 (EV 17.33b - Net Debt -246.6m = Equity 17.58b / Shares 28.4m; r=9.66% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 91.54 | EPS CAGR: 31.13% | SUE: 2.20 | # QB: 2
Revenue Correlation: 97.80 | Revenue CAGR: 22.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.09 | Chg7d=+0.001 | Chg30d=+0.253 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-12-31): EPS=17.37 | Chg7d=-0.018 | Chg30d=+0.859 | Revisions Net=+8 | Growth EPS=+13.7% | Growth Revenue=+10.9%
EPS next Year (2027-12-31): EPS=19.17 | Chg7d=-0.021 | Chg30d=+0.794 | Revisions Net=+7 | Growth EPS=+10.3% | Growth Revenue=+7.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.4% (Discount Rate 9.8% - Earnings Yield 3.4%)
[Growth] Growth Spread = +9.9% (Analyst 16.3% - Implied 6.4%)
P/E Forward = 26.5957
P/S = 5.0522
P/B = 27.8483
P/EG = 2.2532
Revenue TTM = 2.53b USD
EBIT TTM = 537.7m USD
EBITDA TTM = 551.9m USD
Long Term Debt = 113.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 23.2m USD (from shortTermDebt, last quarter)
Debt = 250.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -246.6m USD (from netDebt column, last quarter)
Enterprise Value = 12.54b USD (12.78b + Debt 250.5m - CCE 497.0m)
Interest Coverage Ratio = -115.7 (Ebit TTM 537.7m / Interest Expense TTM -4.65m)
EV/FCF = 17.69x (Enterprise Value 12.54b / FCF TTM 708.7m)
FCF Yield = 5.65% (FCF TTM 708.7m / Enterprise Value 12.54b)
FCF Margin = 28.01% (FCF TTM 708.7m / Revenue TTM 2.53b)
Net Margin = 17.83% (Net Income TTM 451.1m / Revenue TTM 2.53b)
Gross Margin = 30.06% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.77b) / Revenue TTM)
Gross Margin QoQ = 28.98% (prev 29.84%)
Tobins Q-Ratio = 6.35 (Enterprise Value 12.54b / Total Assets 1.98b)
Interest Expense / Debt = 3.15% (Interest Expense 7.88m / Debt 250.5m)
Taxrate = 13.84% (21.7m / 156.8m)
NOPAT = 463.3m (EBIT 537.7m * (1 - 13.84%))
Current Ratio = 0.74 (Total Current Assets 989.6m / Total Current Liabilities 1.34b)
Debt / Equity = 0.55 (Debt 250.5m / totalStockholderEquity, last quarter 459.1m)
Debt / EBITDA = -0.45 (Net Debt -246.6m / EBITDA 551.9m)
Debt / FCF = -0.35 (Net Debt -246.6m / FCF TTM 708.7m)
Total Stockholder Equity = 379.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.13% (Net Income 451.1m / Total Assets 1.98b)
RoE = 118.8% (Net Income TTM 451.1m / Total Stockholder Equity 379.7m)
RoCE = 109.0% (EBIT 537.7m / Capital Employed (Equity 379.7m + L.T.Debt 113.6m))
RoIC = 122.0% (NOPAT 463.3m / Invested Capital 379.7m)
WACC = 9.66% (E(12.78b)/V(13.03b) * Re(9.80%) + D(250.5m)/V(13.03b) * Rd(3.15%) * (1-Tc(0.14)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.60%
[DCF] Terminal Value 76.05% ; FCFF base≈654.1m ; Y1≈806.9m ; Y5≈1.37b
[DCF] Fair Price = 619.4 (EV 17.33b - Net Debt -246.6m = Equity 17.58b / Shares 28.4m; r=9.66% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 91.54 | EPS CAGR: 31.13% | SUE: 2.20 | # QB: 2
Revenue Correlation: 97.80 | Revenue CAGR: 22.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.09 | Chg7d=+0.001 | Chg30d=+0.253 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-12-31): EPS=17.37 | Chg7d=-0.018 | Chg30d=+0.859 | Revisions Net=+8 | Growth EPS=+13.7% | Growth Revenue=+10.9%
EPS next Year (2027-12-31): EPS=19.17 | Chg7d=-0.021 | Chg30d=+0.794 | Revisions Net=+7 | Growth EPS=+10.3% | Growth Revenue=+7.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.4% (Discount Rate 9.8% - Earnings Yield 3.4%)
[Growth] Growth Spread = +9.9% (Analyst 16.3% - Implied 6.4%)